GIM
UTHR icon

Greylin Investment Management’s United Therapeutics UTHR Stock Holding History

Greylin Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$430K Sell
1,350
-75
-5% -$19.9K 0.07% 62
2024
Q1 		$327K Sell
1,425
-25
-2% -$5.64K 0.05% 62
2023
Q4 		$319K Sell
1,450
-125
-8% -$28.8K 0.06% 61
2023
Q3 		$356K Hold
1,575
– – 0.06% 58
2023
Q2 		$348K Sell
1,575
-400
-20% -$88.6K 0.06% 57
2023
Q1 		$442K Sell
1,975
-300
-13% -$74K 0.08% 55
2022
Q4 		$633K Sell
2,275
-75
-3% -$18.9K 0.12% 49
2022
Q3 		$492K Sell
2,350
-50
-2% -$11.2K 0.1% 51
2022
Q2 		$566K Sell
2,400
-150
-6% -$30.5K 0.11% 51
2022
Q1 		$457K Sell
2,550
-6,891
-73% -$1.31M 0.08% 60
2021
Q4 		$2.04M Sell
9,441
-111
-1% -$21.8K 0.38% 38
2021
Q3 		$1.76M Sell
9,552
-4,660
-33% -$918K 0.36% 40
2021
Q2 		$2.55M Sell
14,212
-18,024
-56% -$3.43M 0.49% 34
2021
Q1 		$5.39M Sell
32,236
-3,588
-10% -$598K 1.12% 21
2020
Q4 		$5.44M Sell
35,824
-17,365
-33% -$2.28M 1.27% 17
2020
Q3 		$5.37M Sell
53,189
-61,979
-54% -$6.8M 1.43% 15
2020
Q2 		$13.9M Sell
115,168
-18,755
-14% -$2.11M 3.93% 6
2020
Q1 		$12.7M Sell
133,923
-23,293
-15% -$2.21M 3.95% 5
2019
Q4 		$13.8M Sell
157,216
-20,445
-12% -$1.8M 3.06% 10
2019
Q3 		$14.2M Buy
177,661
+38,683
+28% +$3.12M 3.38% 8
2019
Q2 		$10.8M Buy
138,978
+21,200
+18% +$1.98M 2.44% 11
2019
Q1 		$13.8M Sell
117,778
-3,015
-2% -$351K 3.1% 9
2018
Q4 		$13.2M Buy
+120,793
New +$14M 3.15% 10
2018
Q3 		– Sell
-118,703
Closed -$13.4M – 82
2018
Q2 		$13.4M Buy
118,703
+80,006
+207% +$8.79M 2.91% 9
2018
Q1 		$4.35M Buy
+38,697
New +$4.92M 0.94% 20
2017
Q4 		– Sell
-3,375
Closed -$396K – 78
2017
Q3 		$396K Buy
3,375
+400
+13% +$51.1K 0.09% 60
2017
Q2 		$386K Buy
2,975
+885
+42% +$110K 0.09% 62
2017
Q1 		$283K Buy
+2,090
New +$317K 0.07% 70

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Greylin Investment Management's UTHR Position: Q2 2024 in Review

Greylin Investment Management reduced its United Therapeutics (UTHR) stake by 5.3% in Q2 2024, selling an estimated $19.9K and leaving 1,350 shares worth $430K. The position accounts for 0.07% of the portfolio, ranked #62.

Greylin Investment Management first reported a position in UTHR in Q1 2017 and has held it in 28 quarters since. The position peaked at $14.2M in Q3 2019. 568 funds tracked by Wall St. Rank hold UTHR as of Q2 2024.

  • Greylin Investment Management held 1,350 shares of United Therapeutics worth $430K as of Q2 2024.
  • Greylin Investment Management sold 75 United Therapeutics shares in Q2 2024, an estimated $19.9K.
  • United Therapeutics made up 0.07% of Greylin Investment Management's portfolio in Q2 2024, its #62 holding.
  • Greylin Investment Management first reported a position in United Therapeutics in Q1 2017 and has held it in 28 quarters since.
  • Greylin Investment Management's United Therapeutics position peaked at $14.2M in Q3 2019.
  • 568 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2024.

Based on Greylin Investment Management's 13F filing for Q2 2024, filed 19 Jul 2024.